Riabni Side Effects
Generic name: rituximab
Medically reviewed by Drugs.com. Last updated on May 14, 2023.
Note: This document contains side effect information about rituximab. Some dosage forms listed on this page may not apply to the brand name Riabni.
Applies to rituximab: intravenous solution.
Warning
Intravenous route (Solution)
Fatal infusion-related reactions may occur within 24 hours of rituximab infusion; approximately 80% of fatal reactions occurred with the first infusion. Monitor patients and discontinue rituximab infusion after severe reactions. Severe and potentially fatal mucocutaneous reactions can occur. Reactivation of hepatitis B virus (HBV) may occur; in some cases, it results in fulminant hepatitis, hepatic failure, or death. Screen patients for HBV infection prior to treatment. Progressive multifocal leukoencephalopathy (PML) and death can also occur.
Intravenous route (Solution)
Warning: Fatal Infusion Reactions, Severe Mucocutaneous Reactions, Hepatitis B Virus Reactivation, and Progressive Multifocal LeukoencephalopathyFatal infusion-related reactions within 24 hours of rituximab infusion; approximately 80% of fatal infusion reactions occurred with first infusion. Monitor patients and discontinue rituximab-pvvr infusion for severe reactions.Severe mucocutaneous reactions, some with fatal outcomesHepatitis B virus (HBV) reactivation, in some cases resulting in fulminant hepatitis, hepatic failure, and deathProgressive multifocal leukoencephalopathy (PML) resulting in death
Intravenous route (Solution)
Fatal infusion reactions may occur within 24 hours of rituximab infusion; approximately 80% of fatal reactions occurred with the first infusion. Monitor patients and discontinue rituximab-abbs infusion for severe reactions. Severe and potentially fatal mucocutaneous reactions can occur. Reactivation of hepatitis B virus (HBV) may occur with some cases resulting in fulminant hepatitis, hepatic failure, or death. Screen patients for HBV infection prior to treatment. Progressive multifocal leukoencephalopathy (PML), including fatal PML, can also occur.
Intravenous route (Solution)
Warning: Fatal Infusion-Related Reactions, Severe Mucocutaneous Reactions, Hepatitis B Virus Reactivation, and Progressive Multifocal LeukoencephalopathyFatal infusion-related reactions within 24 hours of rituximab infusion; approximately 80% of fatal reactions occurred with first infusion. Monitor patients and discontinue rituximab-arrx infusion for severe reactions.Severe mucocutaneous reactions, some with fatal outcomes.Hepatitis B virus (HBV) reactivation, in some cases resulting in fulminant hepatitis, hepatic failure, and death.Progressive multifocal leukoencephalopathy (PML) resulting in death.
Serious side effects of Riabni
Along with its needed effects, rituximab (the active ingredient contained in Riabni) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor or nurse immediately if any of the following side effects occur while taking rituximab:
More common
- Back pain
- black, tarry stools
- bleeding gums
- bloating or swelling of the face, arms, hands, lower legs, or feet
- blood in the urine or stools
- blurred vision
- body aches or pain
- burning or stinging of the skin
- chest pain or tightness
- chills
- confusion
- cough
- difficulty with breathing
- dizziness, faintness, or lightheadedness when getting up suddenly from a lying or sitting position
- drowsiness
- dry mouth
- ear congestion
- fever
- flushed, dry skin
- fruit-like breath odor
- headache
- hives or welts, itching, rash
- increased hunger
- increased thirst
- increased urination
- large, hive-like swelling on the face, eyelids, lips, tongue, throat, hands, legs, feet, or genitals
- lower back or side pain
- nausea
- nervousness
- noisy breathing
- pain or tenderness around the eyes and cheekbones
- painful cold sores or blisters on the lips, nose, eyes, or genitals
- painful or difficult urination
- pale skin
- pinpoint red spots on the skin
- pounding in the ears
- seizures
- slow or fast heartbeat
- sneezing
- sore throat
- sores, ulcers, or white spots in the mouth or on the lips
- stomach pain
- stuffy or runny nose
- sweating
- swelling of the tongue or throat
- swollen glands
- tingling of the hands or feet
- trouble breathing
- unusual bleeding or bruising
- unusual tiredness or weakness
- unusual weight gain or loss
- vomiting
Less common
- Blistering, peeling, or loosening of the skin
- blisters on the trunk, scalp, or other areas
- burning, crawling, itching, numbness, prickling, “pins and needles”, or tingling feeling
- decreased frequency and amount of urine
- diarrhea
- difficulty with moving
- discouragement
- feeling sad or empty
- irregular heartbeat
- irritability
- joint or muscle pain
- loss of appetite
- loss of interest or pleasure
- lump or growth on the skin
- muscle cramp, pain, or stiffness
- numbness or tingling in the hands, feet, or lips
- painful blisters on the trunk of the body
- pain or redness at the injection site
- pain, swelling, or redness in the joints
- pounding or irregular heartbeat or pulse
- red skin lesions, often with a purple center
- red, itchy lining of the eye
- redness of the face, neck, arms, and occasionally, upper chest
- stabbing pain
- trouble concentrating
- trouble sleeping
Incidence not known
- Blue-yellow color blindness
- blurred vision or other change in vision
- burning or stinging of the skin
- decreased vision
- dilated neck veins
- dry cough
- extreme tiredness or weakness
- eye pain, tearing
- feeling of discomfort, illness, or weakness
- irregular breathing
- nosebleed
- painful cold sores or blisters on the lips, nose, eyes, or genitals
- sensitivity of the eye to light
- severe stomach pain
- severe vomiting, sometimes with blood
- sores, welts, or blisters
- stomach cramps
- swelling, stiffness, redness, or warmth around many joints
- swollen lymph glands
- vision loss
Other side effects of Riabni
Some side effects of rituximab may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.
Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
More common
- Fear
- lack or loss of strength
- loss or thinning of the hair
- night sweats
- throat irritation
Less common
- Agitation or anxiety
- bone pain
- burning, dry, or itching eyes
- change in taste
- discharge, excessive tearing
- dry eyes
- excessive muscle tone
- feeling of constant movement of self or surroundings
- heartburn
- increase in body movements
- lightheadedness
- muscle tension
- redness, pain, or swelling of the eye, eyelid, or inner lining of the eyelid
- sensation of spinning
- sleepiness
- swelling of the stomach
For Healthcare Professionals
Applies to rituximab: intravenous solution.
Cardiovascular
Very common (10% or more): Hypotension (10%)
Common (1% to 10%): Hypertension, orthostatic hypotension, myocardial infarction, arrhythmia, atrial fibrillation, tachycardia
Uncommon (0.1% to 1%): Left ventricular failure, supraventricular tachycardia, ventricular tachycardia, angina, myocardial ischemia, bradycardia
Very rare (less than 0.01%): Heart failure, vasculitis (predominately cutaneous), leukocytoclastic vasculitis[Ref]
Dermatologic
Very common (10% or more): Night sweats (15%), rash (15%), pruritus (14%), angioedema (11%), alopecia
Common (1% to 10%): Flushing, urticaria, skin disorder
Very rare (less than 0.01%): Severe bullous skin reactions, Stevens-Johnson Syndrome, toxic epidermal necrolysis (Lyell's Syndrome)
Postmarketing reports: Severe mucocutaneous reactions[Ref]
Gastrointestinal
Very common (10% or more): Nausea (23%), abdominal pain (14%), diarrhea (10%), vomiting (10%)
Common (1% to 10%): Throat irritation, dysphagia, stomatitis, constipation, dyspepsia, anorexia
Uncommon (0.1% to 1%): Abdominal enlargement
Frequency not reported: GI perforation
Postmarketing reports: Bowel obstruction[Ref]
Hematologic
Very common (10% or more): Lymphopenia (48%), leukopenia (14%), neutropenia (14%), thrombocytopenia (12%)
Common (1% to 10%): Blood lactate dehydrogenase (LDH) increased, pancytopenia, granulocytopenia
Uncommon (0.1% to 1%): Anemia, coagulation disorders, aplastic anemia, hemolytic anemia, lymphadenopathy, transient aplastic anemia, hemolytic anemia
Postmarketing reports: Late neutropenia, marrow hypoplasia, Grade 3 to 4 prolonged or late-onset neutropenia, hyperviscosity syndrome in Waldenstrom's macroglobulinemia, prolonged hypogammaglobulinemia[Ref]
Hepatic
Very common (10% or more): Increased ALT (13%)
Frequency not reported: Hepatitis B reactivation with fulminant hepatitis, hepatic failure[Ref]
Hypersensitivity
Common (1% to 10%): Hypersensitivity
Rare (0.01% to 0.1%): Anaphylaxis
Very rare (less than 0.01%): Tumor lysis syndrome, cytokine release syndrome, serum sickness[Ref]
Immunologic
Very common (10% or more): Infection (bacterial, viral) (31%)
Common (1% to 10%): Sepsis, febrile infection, herpes zoster, fungal infections, infections of unknown etiology, acute bronchitis, sinusitis
Rare (less than 0.1%): Serious viral infections
Postmarketing reports: Lupus-like syndrome, serum sickness, increase in fatal infections in HIV-associated lymphoma, increased incidence of Grade 3 and 4 infections[Ref]
Local
Very common (10% or more): Acute infusion reactions (e.g., pain, fever, chills, rigors, pruritus, urticaria/rash, angioedema, sneezing, throat irritation, cough, and/or bronchospasm, with or without associated hypotension or hypertension) (27%)[Ref]
Metabolic
Very common (10% or more): Hypophosphatemia (12%)
Common (1% to 10%): Hyperglycemia, peripheral edema, hyperuricemia, weight decrease, peripheral edema, face edema, increased LDH, hypocalcemia[Ref]
Musculoskeletal
Very common (10% or more): Back pain (10%), myalgia (10%), arthralgia (10%)
Common (1% to 10%): Neck pain, hypertonia
Frequency not reported: Polyarticular arthritis[Ref]
Nervous system
Very common (10% or more): Headache (19%), dizziness (10%)
Common (1% to 10%): Pyrexia, paresthesia, hypoesthesia
Uncommon (0.1% to 1%): Dysgeusia
Postmarketing reports: Posterior reversible encephalopathy syndrome (PRES)/reversible posterior leukoencephalopathy syndrome (RPLS)[Ref]
Ocular
Common (1% to 10%): Lacrimation disorder, conjunctivitis
Very rare (less than 0.01%): Severe vision loss
Postmarketing reports: Uveitis, optic neuritis[Ref]
Oncologic
Postmarketing reports: Disease progression of Kaposi's sarcoma[Ref]
Other
Very common (10% or more): Fever (53%), chills (33%), asthenia (26%), fatigue (13%), pain (12%)
Common (1% to 10%): Migraine, asthenia, tinnitus, ear pain, tumor pain, flushing, malaise, cold syndrome, shivering, multi-organ failure
Very rare (less than 0.01%): Hearing loss[Ref]
Psychiatric
Common (1% to 10%): Anxiety, depression, nervousness, agitation, insomnia[Ref]
Renal
Very rare (less than 0.01%): Renal failure[Ref]
Respiratory
Very common (10% or more): Cough (13%), rhinitis (12%), epistaxis (11%), dyspnea (10%), bronchitis
Common (1% to 10%): Bronchospasm, sinusitis, pneumonia, chest pain
Uncommon (0.1% to 1%): Upper respiratory tract infection, asthma, bronchiolitis obliterans (fatal), lung disorder, hypoxia
Rare (0.01% to 0.1%): Interstitial lung disease
Very rare (less than 0.01%): Respiratory failure
Frequency not reported: Lung infiltration
Postmarketing reports: Pleuritis[Ref]
Frequently asked questions
- What are the new drugs for the treatment of rheumatoid arthritis (RA)?
- What are biosimilar drugs?
- How many biosimilars have been approved in the United States?
- Is Truxima a chemotherapy drug?
- What is the success rate of Rituxan (rituximab) in patients with blood cancers?
- What is the difference between Truxima and Rituxan?
- What causes infusion reactions to rituximab?
- What is the success rate of Rituxan (rituximab) in rheumatoid arthritis?
- Are lung nodules common after Bendeka & Rituxan therapy?
- What is the difference between Rituxan and Rituxan Hycela?
More about Riabni (rituximab)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: CD20 monoclonal antibodies
- Breastfeeding
- En español
Patient resources
Other brands
Professional resources
Related treatment guides
References
1. "Product Information. Rituxan (rituximab)." Genentech (2001):
2. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
3. Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online. http://www.appco.com.au/appguide/default.asp" (2006):
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Some side effects may not be reported. You may report them to the FDA.